July 12, 2016
Bayer and X-Chem, Inc., a privately held biotechnology company that focuses on applying its innovative drug discovery capabilities to the generation of novel small molecule therapeutics, have entered into an expanded global collaboration for drug discovery across multiple therapeutic areas and target classes. This new agreement will extend Bayer’s access to X-Chem’s DEX™ technology which is based on DNA-encoded libraries of small molecules with more than 120 billion molecules. The main goal of the collaboration is to discover innovative lead structures for complex drug targets in areas of high unmet medical need.
“Bayer and X-Chem have built a strong relationship delivering outcomes that have exceeded expectations. Complementing our in-house expertise with technologies and know-how of excellent partners is an integral part of our innovation strategy at Bayer. We have identified the DEX™ platform as a highly valuable extension for our drug discovery efforts. We are looking forward to working with X-Chem on some of our highest-priority targets, for which X-Chem’s platform is ideally suited,” said Professor Andreas Busch, member of the Executive Committee of Bayer AG’s Pharmaceuticals Division and Head of Drug Discovery.
Rick Wagner, Ph.D., Chief Executive Officer of X-Chem, said: “X-Chem is making significant inroads toward the discovery of small molecule drug candidates using its ultra-large screening library. With multiple successes across our partnerships, the DEX™ platform has been broadly validated to deliver novel chemical entities against a wide array of targets, including difficult targets. We are fortunate to have Bayer as a major strategic partner, and we are looking forward to expanding this strong and successful relationship. X-Chem is excited to continue working with Bayer on a wider array of diseases and conditions with significant unmet medical needs.”Bayer Expands its Drug Discovery Collaboration with X-Chem to Discover Novel Medicineslast edit: 2016-07-19T18:00:24+00:00da